‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand

Published:November 09, 2015DOI:https://doi.org/10.1016/j.ijcard.2015.11.067



      Anticoagulants such as warfarin and dabigatran can significantly reduce the risk of stroke in individuals with atrial fibrillation that may lead to increased risk of bleeding, especially in older people. Evidence for bleeding risks with anticoagulants within the context of doses, multimorbidity and impaired renal function in real world setting is lacking.
      Therefore we aimed to assess and compare real world bleeding risks with warfarin and dabigatran. Secondary analyses involved examining risk of fatal haemorrhages.

      Methods and results

      We formed two inception cohorts of propensity score (PS) matched older patients (≥65 years), who initiated dabigatran or warfarin between July 2011 and December 2012. A total of 4835 dabigatran users were matched to 4385 warfarin users in dose independent binary PS matching. A dose dependent PS matching resulted in 2383 warfarin, 2153 dabigatran 150 mg and 3395 dabigatran 110 mg users. In the first cohort, compared to warfarin, the hazard ratios (95% confidence intervals) for dabigatran were 0.45 (0.37–0.55) for any haemorrhage; 1.16 (0.87–1.56) for gastrointestinal haemorrhage; and 0.29 (0.09–0.86) for intracerebral haemorrhage. Similar associations were observed in the first 30 days of treatment. In dose dependent matched cohort, the risk of any haemorrhage was lower in individuals receiving dabigatran 110 mg (HR; 95% CI: 0.40 (0.31–0.52)) and 150 mg (HR; 95% CI: 0.29 (0.19–0.41)) compared to warfarin.


      The risk of any haemorrhage and intracerebral haemorrhage was lower in dabigatran users compared to warfarin users. Importantly no increased risk of gastrointestinal haemorrhage was found in dabigatran users. The incidence rates for any haemorrhage were found to be higher in first 30 days of any anticoagulant treatment, but hazard ratios remained similar during the study period.


      AF (atrial fibrillation), GI (gastrointestinal), NHI (National Health Index), DHB (District Health Board), CDS (chronic disease score)


      To read this article in full you will need to make a payment


      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prystowsky E.N.
        • Benson D.W.
        • Fuster V.
        • Hart R.G.
        • Kay G.N.
        • Myerburg R.J.
        • et al.
        Management of patients with atrial fibrillation: a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology.
        Am. Heart Assoc. Circ. 1996; 93: 1262-1277
        • Camm A.J.
        • Kirchhof P.
        • GYH L.
        • Schotten U.
        • Savelieva I.
        • Ernst S.
        • et al.
        Guidelines for the management of atrial fibrillation.
        • Camm A.J.
        • Lip G.Y.H.
        • De Caterina R.
        • Savelieva I.
        • Atar D.
        • Hohnloser S.H.
        • et al.
        2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation.
      1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
        Arch. Intern. Med. 1994; 154: 1449-1457
        • Gullov A.L.
        • Koefoed B.G.
        • Petersen P.
        Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation.
        Arch. Intern. Med. 1999; 159: 1322-1328
        • Hart R.G.
        • Diener H.C.
        • Yang S.
        • Connolly S.J.
        • Wallentin L.
        • Reilly P.A.
        • et al.
        Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
        Stroke. 2012; 43: 1511-1517
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N. Engl. J. Med. 2009; 361: 1139-1151
        • Harper P.
        • Young L.
        • Merriman E.
        Bleeding risk with dabigatran in the frail elderly.
        N. Engl. J. Med. 2012; 366: 864-866
        • Sorensen R.
        • Gislason G.
        • Torp-Pedersen C.
        • Olesen J.B.
        • Fosbol E.L.
        • Hvidtfeldt M.W.
        • et al.
        Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.
        BMJ Open. 2013; 3
        • Fontaine G.V.
        • Mathews K.D.
        • Woller S.C.
        • Stevens S.M.
        • Lloyd J.F.
        • Evans R.S.
        Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
        Clin. Appl. Thromb. Hemost. 2014; 20: 665-672
        • Gomes T.
        • Mamdani M.M.
        • Holbrook A.M.
        • Paterson J.M.
        • Hellings C.
        • Juurlink D.N.
        Rates of hemorrhage during warfarin therapy for atrial fibrillation.
        CMAJ. 2013; 185: E121-E127
        • Larsen T.B.
        • Rasmussen L.H.
        • Skjoth F.
        • Due K.M.
        • Callreus T.
        • Rosenzweig M.
        • et al.
        Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study.
        J. Am. Coll. Cardiol. 2013; 61: 2264-2273
        • Hylek E.M.
        • Evans-Molina C.
        • Shea C.
        • Henault L.E.
        • Regan S.
        Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
        Circulation. 2007; 115: 2689-2696
        • Perera V.
        • Bajorek B.V.
        • Matthews S.
        • Hilmer S.N.
        The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation.
        Age Ageing. 2009; 38: 156-162
        • Graham D.J.
        • Reichman M.E.
        • Wernecke M.
        • Zhang R.
        • Southworth M.R.
        • Levenson M.
        • et al.
        Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
        Circulation. 2015; 131: 157-164
        • Jun M.
        • James M.T.
        • Manns B.J.
        • Quinn R.R.
        • Ravani P.
        • Tonelli M.
        • et al.
        The Association Between Kidney Function and Major Bleeding in Older Adults With Atrial Fibrillation Starting Warfarin Treatment: Population Based Observational Study.
        • Larsen T.B.
        • Rasmussen L.H.
        • Gorst-Rasmussen A.
        • Skjoth F.
        • Lane D.A.
        • Lip G.Y.
        Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
        Am. J. Med. 2014; 127 (e5): 1172-1178
        • Hilmer S.N.
        • Gnjidic D.
        • Abernethy D.R.
        Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
        J. Gerontol. A Biol. Sci. Med. Sci. 2012; 67: 181-188
        • Shafeeq H.
        • Tran T.H.
        New oral anticoagulants for atrial fibrillation: are they worth the risk?.
        Pharmacol. Ther. 2014; 39: 54-64
        • Feinberg J.
        • Grabowitz L.
        • Rotman-Pikielny P.
        • Berla M.
        • Levy Y.
        Dabigatran etexilate linked to fatal gastrointestinal hemorrhage.
        Isr. Med. Assoc. J. 2014; 16: 388-389
        • Kernan L.
        • Ito S.
        • Shirazi F.
        • Boesen K.
        Fatal gastrointestinal hemorrhage after a single dose of dabigatran.
        Clin. Toxicol. (Phila.). 2012; 50: 571-573
        • Salmela B.
        • Joutsi-Korhonen L.
        • Armstrong E.
        • Lassila R.
        Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.
        Semin. Thromb. Hemost. 2012; 38: 23-30
        • Bellamy L.
        • Rosencher N.
        • Eriksson B.
        Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
        Patient Prefer. Adherence. 2009; 3: 173-177
        • Jayathissa S.
        • Gommans J.
        • Harper P.
        Stroke thrombolysis in patients taking dabigatran.
        Intern. Med. J. 2013; 43: 826-828
        • Duffull S.B.
        • Wright D.F.
        • Al-Sallami H.S.
        • Zufferey P.J.
        • Faed J.M.
        Dabigatran: rational dose individualisation and monitoring guidance is needed.
        N. Z. Med. J. 2012; 125: 148-154
        • Chin P.K.
        • Vella-Brincat J.W.
        • Barclay M.L.
        • Begg E.J.
        Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?.
        Br. J. Clin. Pharmacol. 2012; 74: 734-740
        • Chin P.K.
        • Wright D.F.
        • Patterson D.M.
        • Doogue M.P.
        • Begg E.J.
        A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
        Br. J. Clin. Pharmacol. 2014; 78: 599-609
      2. National Minimum Dataset (Hospital Events) data dictionary.
        Ministry of Health New Zealand, 2014
      3. The International statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM).
        6th ed. National Centre for Classification in Health, Lidcombe, NSW2008
      4. Data dictionaries.
        Ministry of Health New Zealand, 2014
      5. Pharmaceutical Claims Data Mart.
        Ministry of Health, New Zealand2012
      6. Mortality Collection data dictionary.
        Ministry of Health, New Zealand2014
        • Johnson E.S.
        • Bartman B.A.
        • Briesacher B.A.
        • Fleming N.S.
        • Gerhard T.
        • Kornegay C.J.
        • et al.
        The incident user design in comparative effectiveness research.
        Pharmacoepidemiol. Drug Saf. 2013; 22: 1-6
        • Bryer J.M.
        TriMatch: An R Package for Propensity Score Matching of Non-binary Treatments.
        • Von Korff M.
        • Wagner E.H.
        • Saunders K.
        A chronic disease score from automated pharmacy data.
        J. Clin. Epidemiol. 1992; 45: 197-203
        • Nishtala P.S.
        • Narayan S.W.
        • Wang T.
        • Hilmer S.N.
        Associations of drug burden index with falls, general practitioner visits, and mortality in older people.
        Pharmacoepidemiol. Drug Saf. 2014; 23: 753-758
        • Putnam K.G.
        • Buist D.S.
        • Fishman P.
        • Andrade S.E.
        • Boles M.
        • Chase G.A.
        • et al.
        Chronic disease score as a predictor of hospitalization.
        Epidemiology. 2002; 13: 340-346
      7. Dabigatran etexilate- NZF. New Zealand Formulary (NZF); 2014.

      8. Oral Anticoagulants-warfarin Sodium.
        PHARMAC, the Pharmaceutical Management Agency, 2014
      9. Oral Anticoagulants-dabigatran.
        PHARMAC, the Pharmaceutical Management Agency, 2014
        • Kozma C.M.
        • Dickson M.
        • Phillips A.L.
        • Meletiche D.M.
        Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.
        Patient Prefer. Adherence. 2013; 7: 509-516
        • Roldan V.
        • Marin F.
        • Manzano-Fernandez S.
        • Gallego P.
        • Vilchez J.A.
        • Valdes M.
        • et al.
        The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
        J. Am. Coll. Cardiol. 2013; 62: 2199-2204
        • Hanger H.C.
        • Fletcher V.J.
        • Wilkinson T.J.
        • Brown A.J.
        • Frampton C.M.
        • Sainsbury R.
        Effect of aspirin and warfarin on early survival after intracerebral haemorrhage.
        J. Neurol. 2008; 255: 347-352
        • Arnason T.
        • Wells P.S.
        • van Walraven C.
        • Forster A.J.
        Accuracy of coding for possible warfarin complications in hospital discharge abstracts.
        Thromb. Res. 2006; 118: 253-262